Damoctocog Alfa Pegol
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Damoctocog Alfa Pegol |
| DrugBank ID | DB14700 |
| Brand Names (EU) | Jivi |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 97.67% |
Approved Indication (EMA)
Treatment and prophylaxis of bleeding in previously treated patients (PTPs) ≥ 7 years of age with haemophilia A (congenital factor VIII deficiency).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary release disorder of platelets | 97.67% | DL |
| 2 | Glanzmann thrombasthenia | 97.57% | DL |
| 3 | pseudo-von Willebrand disease | 96.85% | DL |
| 4 | severe nonproliferative diabetic retinopathy | 95.12% | DL |
| 5 | hemorrhagic disorder due to a constitutional thrombocytopenia | 93.46% | DL |
| 6 | bleeding diathesis due to a collagen receptor defect | 93.16% | DL |
| 7 | tumor of testis and paratestis | 92.95% | DL |
| 8 | bronchial adenomas/carcinoids childhood | 92.91% | DL |
| 9 | non-seminomatous lesion | 92.91% | DL |
| 10 | ductal or ductular proliferation | 92.91% | DL |
| 11 | chondroid hamartoma | 92.91% | DL |
| 12 | progressive multiple sclerosis | 92.89% | DL |
| 13 | thyroglossal duct cyst | 92.74% | DL |
| 14 | cervical neuroblastoma | 92.73% | DL |
| 15 | mesenchymoma | 92.71% | DL |
| 16 | cystic neoplasm | 92.68% | DL |
| 17 | epiglottis neoplasm | 92.66% | DL |
| 18 | schwannoma of jugular foramen | 92.63% | DL |
| 19 | benign neoplasm of floor of mouth | 92.61% | DL |
| 20 | benign neoplasm of tongue | 92.56% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.